EQL Pharma AB (publ) at its annual general meeting of 2020 approved the resolution that the Nomination Committee shall be convened by the Chairman of the Board and consist of a representative of each of the three largest shareholders in terms of the number of votes at the end of December 2020. At the end of December, the three largest shareholders were Cadila Pharmaceuticals Ltd. and Fårö Capital AB and Emanuel Eriksson. All have agreed to participate in the nomination committee's work. Prior to the 2021 Annual General Meeting, the Nomination Committee consists of Christer Fåhraeus (appointed by Fårö Capital AB), Rajiv I Modi (appointed by Cadila Pharmaceuticals Ltd.), and Emanuel Eriksson.